Clinical study of D2 lymphadenectomy for gastric cancer

Chinese Journal of Cancer Prevention and Treatment

Volumn 14, Issue 24, 2007, Pages 1891-1893

  Li, Wei Wen ^a   Chen, Li Kun ^a   Huang, He ^a   Tan, Jie Mei ^a   Li, Ming Yi ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

D2 lymph node excision; Postoperative complications; Prognosis; Stomach neoplasms surgery

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POSTOPERATIVE COMPLICATION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SAFETY; STOMACH CANCER; SURGICAL MORTALITY; SURVIVAL RATE;

EID: 77953416324     PISSN: 16735269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Hanazaki K, Mochizuki Y, Machida T, et al. Post-operative chemo-therapy in non-curative gastrectomy for advanced gastric cancer[J]. Hepatogastroenterology, 1999, 46 (26):1238-1243.
2. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial offluorouracil alone versus fluorouracil p lus cisp latin versus uracil andtegafur p lusmitomycin in patients with unresectable, advanced gastric cancer: The Japan ClinicalOncology Group Study (JCOG9205)[J]. J Clin Oncol, 2002, 21(1):54-59.
3. Tsukioka Y, Matsumura Y, Hamaguchi T, et al. Comp lete response ahieved following administration of S21 in patientwith adrenal glandmetastasis of 52FU-resistant gastric cancer: a case report[J]. Jpn JClin Oncol, 2001,31(9):450-453.
4. Osugi H, Takemura M. Oral fluoropyrimidine anticancer drug TS21for gastric cancer patients with peritoneal dissemination [J]. Oncol Rep, 2002, 9(4):811-815.
5. Layke J C, Lopez P P. Gastric cancer: diagnosis and treatment options[J]. Am Fam Physician,2004,69(5):1133.
6. JUAN ROSAI. Chinese source.
7. Edwards P, Blackshaw G R, Lewis W G, et al. Prospective comparison of D1 vs modified D2 gast rectomy for carcinoma[J]. Br J Cancer, 2004, 90(10):1888.
8. Ichikura T, Ogawa T, Chochi K, et al. Minimum number of lymph nodes that should be examined for the International Union Against Cancer/American Joint Committee on Cancer TNM classification of gastric carcinoma[J]. World J Surg, 2003, 27 (3):330.
9. Kikuchi S, Katada N, Sakuramoto S, et al. Factors associated with pN3 stage tumors according to the TNM classification in advanced gast ric cancer[J]. Hepatogast roenterology, 2003, 50 (53):1723.
10. Nitti D, Marchet A, Olivieri M, et al. Lymphadenectomy in patients with gast ric cancer. A critical review[J]. Suppl Tumori, 2003, 2(5):S35.
11. Verreet P R. Stage-adapted radical principles in gastric carcinoma[J]. Schweiz Rundsch Med Prax, 1998, 87(13):447.
12. Roviello F, Marrelli D, Morgagni P, et al. Benefit s of extended lymphadenectomy in patient s wit h gast ric carcinoma wit h metastasis to second level lymph nodes. An Italian multicenter study [J]. Chir Ital, 2003, 55(4):491.
13. Ikeguchi M, Oka S, Gomyo Y, et al. Prognostic benefit of extended radical lymphadenectomy for patient s with gastric cancer [J]. Anticancer Res, 2000, 20(2B):1285.
14. Kajitani T. The gengral rules for thegastric cancer study in surgery and pathology: Part1-Clinical classification[J]. Jpn J Surg, 1981,11(2):127-139.
15. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: Morbidity and mortality results form a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group Study 9501 [J]. J Clin Oncol,2004,22:2767-2773.
16. Fujii M, Sasaki J, Nakajina T. State of the art in the treatment of gastric cancer:Fome the 71st Japanese Gastric Cancer Congress [J]. Gastric Cancer,1999,2:151-157.
17. Sano T, Katai H, Sasako M, et al. One thousand consecutive gastrectomies with operative mortality[J]. Br J Surg, 2002, 89: 123.